Thrombosis in vasculitis: from pathogenesis to treatment

In recent years, the relationship between inflammation and thrombosis has been deeply investigated and it is now clear that immune and coagulation systems are functionally interconnected. Inflammation-induced thrombosis is by now considered a feature not only of autoimmune rheumatic diseases, but also of systemic vasculitides such as Behçet’s syndrome, ANCA-associated vasculitis or giant cells arteritis, especially during active disease. These findings have important consequences in terms of management and treatment. Indeed, Behçet’syndrome requires immunosuppressive agents for vascular involvement rather than anticoagulation or antiplatelet therapy, and it is conceivable that also in ANCA-associated vasculitis or large vessel-vasculitis an aggressive anti-inflammatory treatment during active disease could reduce the risk of thrombotic events in early stages. In this review we discuss thrombosis in vasculitides, especially in Behçet’s syndrome, ANCA-associated vasculitis and large-vessel vasculitis, and provide pathogenetic and clinical clues for the different specialists involved in the care of these patients

Microhardness evaluation of enamel adjacent to an improved GIC sealant after different enamel pre-treatment procedures

Aim This in vitro study was carried out to evaluate the microhardness of enamel adjacent to a glass ionomer cement (GIC) with high fluoride content used as a sealant (Fuji Triage, GC Corp., Japan) after laser, bur or air abrasion treatment procedures. Materials and methods Study design: 200 freshly extracted non-carious human molars were divided into 10 experimental groups according to the enamel pretreatment method: A air abrasion (Mach 4.1 Kreativ Inc., USA); AP, Air abrasion + conditioning with 20% polyacrylic acid (GC cavity conditioner); L, Er, Cr:YSGG laser application (Waterlase, Biolase Technology, Inc., San Clemente, USA); LP, Er, Cr: YSGG laser application and fissure conditioning; B, ameloplasty carried out with a diamond bur especially designed for preparing fissures (Komet #8833); BP, ameloplasty + fissure conditioning; P, application of 20% polyacrylic acid and all fissures sealed with GIC; C, no fissure treatment, the material was applied directly to the fissures (control); R, application of 37% orthophosphoric acid and fissures sealed with a resin-based sealant (Fissurit; Voco, Germany) (control); N, no treatment (control). Half of each group of teeth were left in artificial saliva for one month and the rest for three months. The teeth were then sectioned and microhardness was measured using a Vickers test apparatus. Kruskal-Wallis, Mann-Whitney U and Dunn's multiple comparison tests were carried out (5% significance). Results After one month results regarding hardness at the base and lateral walls of fissures were significantly higher in groups A, AP, L, LP, B, BP, P and C than in groups R and N (p<0.01), but no difference was seen between the treatment procedures. The results after three months produced similar findings with evenly increased values for all groups. Conclusion The results of this study showed that the tested GIC with a higher fluoride content seemed to improve the enamel hardness of the fissure enamel and could be regarded as an alternative material in cases where resin sealant applications are questionable.GC Corporation; Marmara University Scientific Researches CommitteeMarmara University [SAG-d-300609-0269]This study was supported by GC Corporation and Marmara University Scientific Researches Committee (Project No. SAG-d-300609-0269)

Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case

Umit Yavuz Malkan, Gursel Gunes, Eylem Eliacik, Ibrahim Celalettin Haznedaroglu Department of Hematology, School of Medicine, Hacettepe University, Ankara, Turkey Abstract: Thalidomide may be used as a treatment option for pyoderma gangrenosum (PG) and myelodysplastic syndrome (MDS). Herein, we aimed to report a patient who was treated well with thalidomide and whose diagnosis was PG with MDS. A 61-year-old man with painless ecchymotic lesions in his right upper extremity was admitted to the hospital in Isparta, Turkey, in January 2015. The lesions were diagnosed as PG. In his anamnesis, it was found that he was diagnosed with MDS 6 years ago and had been treated with cyclosporine at 2&times;100 mg for 5 years, which was stopped in January 2015. Aspiration from liver lesion revealed the presence of Mycobacterium tuberculosis, so antituberculosis treatment was started. Bone marrow investigation revealed MDS-refractory anemia with excess blasts (7%). For lesions in bilateral upper extremities, thalidomide treatment was started at 50 mg/d. After 1 month from the initiation of thalidomide treatment, the lesions in upper extremities had disappeared. In the literature, there are some reports of patients with PG who were successfully treated with thalidomide. Our patient is a complicated case who simultaneously has MDS, PG, and tuberculosis infection. The reason for thalidomide usage in our patient was the need of immune modulation without immune suppression. Our patient has tolerated the drug well, and excellent response was obtained after 1 month of initiation of thalidomide treatment. To conclude, thalidomide is a very effective drug acting as an immune modulator, which is useful in the clinical management of both MDS and PG. Keywords: pyoderma gangrenosum, thalidomide, myelodysplastic syndrom